Evidence map›Paper›PMID 39984510›Full record

ArticleScientific reports2025

Leuconostoc lactis strain APC 3969 produces a new variant of cyclic bacteriocin leucocyclicin Q and displays potent anti-Clostridium perfringens activity.

Felipe Miceli de Farias, Maria Cecilia Soria, Paula M O'Connor, Xiaohui Huang, Colin Buttimer, Eleni Kamilari, Aiswariya Deliephan, Daragh Hill, Oxana Fursenko, Jonathan Wiese and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Felipe Miceli de Farias *APC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Maria Cecilia Soria *APC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Paula M O'ConnorAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Xiaohui HuangAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Colin ButtimerAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Eleni KamilariAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Aiswariya DeliephanThe Kraft Heinz Company, Chicago, IL, USA.
Daragh HillThe Kraft Heinz Company, Chicago, IL, USA.
Oxana FursenkoThe Kraft Heinz Company, Chicago, IL, USA.
Jonathan WieseThe Kraft Heinz Company, Chicago, IL, USA.
Lorraine DraperAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Catherine StantonAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
Colin HillAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland.
R Paul RossAPC Microbiome Ireland, University College Cork, Cork, T12 YT20, Ireland. p.ross@ucc.ie.

Funding

European Union (ERC, BACtheWINNER) 101054719European Union's Horizon 2020 Research and Innovation Programme under the INSPIRE COFUND Marie Skłodowska-Curie 101034270Science Foundation Ireland (SFI) SFI/ 12/RC/2273_P2
6 · The paper itself

Abstract

Clostridium perfringens is an important foodborne pathogen that produces diverse toxins and is often associated with foodborne gastroenteritis. In this sense, novel biopreservatives with anti-C. perfringens activity are of interest. Among them, bacteriocins produced by lactic acid bacteria stand out as potential candidates. This study describes leucocyclicin C, a novel variant of the bacteriocin leucocyclicin Q, capable of inhibiting C. perfringens. The bacteriocin comprises 61 amino acids, has a molecular mass of 6,081.44 Da, and is produced by the strain Leuconostoc lactis APC 3969. Like many circular bacteriocins, leucocyclicin C has a broad spectrum of activity, is protease resistant, and has high stability against thermic and pH stresses. The leucocyclicin C genetic cluster comprises ten genes instead of the five genes previously described for leucocyclicin Q. Also, this genetic cluster seems to be part of a putative composite transposon. Leucocyclicin C has a minimum inhibitory concentration (MIC) of 3.288 µM against C. perfringens, comparable with other antimicrobial peptides. These results suggest that leucocyclicin C has the potential as a biopreservative for controlling C. perfringens in food.

Indexed as

Anti-Bacterial AgentsBacteriocinsClostridium perfringensLeuconostocMicrobial Sensitivity TestsMultigene FamilyAnti-Bacterial AgentsBacteriocinsCircular bacteriocinClostridium perfringensLeucocyclicin CLeuconostoc lactisVariant

Identifiers

PMID39984510
PMCPMC11845615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.